Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Mar;13(3):189-191.
doi: 10.1111/crj.12998. Epub 2019 Feb 17.

Disseminated herpes zoster following treatment with benralizumab

Ajay Kumar Mishra  1 , Kamal Kant Sahu  1 , Atem James  1
Affiliations
Case Reports

Disseminated herpes zoster following treatment with benralizumab

Ajay Kumar Mishra et al. Clin Respir J. 2019 Mar.

Abstract

Background: Disseminated herpes zoster infection occurs mostly in immunocompromised hosts. There have been recent reports of disseminated zoster with chemotherapeutic regimens and newer monoclonal antibodies.

Case report: The present case describes a 61-year-old patient presenting with disseminated herpes zoster after initiation of benralizumab, an anti-IL-5 monoclonal antibody for severe persistent asthma. His initial vesicular lesions limited to left lumbar dermatomes progressed extensively resulting in dissemination on his body. The diagnosis was confirmed with PCR and he had remarkable clinical improvement with acyclovir and supportive medical management.

Conclusion: Clinical trials have reported an association of mepolizumab, another anti-IL-5 monoclonal antibody with herpes zoster. This report of herpes zoster following initiation of benralizumab might suggest a possibility of a class effect of anti-IL-5 monoclonal antibody.

Keywords: disseminated; immunotherapy; zoster.

PubMed Disclaimer

Publication types